2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Omics Technologies, Bioinformatics, Clinical Procedures, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality Improvement, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, Translational Research, MPN, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Pregnant, Young Adult
PAPER

3799 Myelofibrosis grade improvement in the TQ05105-I-01 Phase I study of rovadicitinib monotherapy in patients with myelofibrosis

Zefeng Xu, Ling Pan2, Zhenya Hong3, Qingsong Yin, PhD4, Xue Lan Zuo5, Wen Qin, MD6, Lihong Li7, Xin Du, MD, PhD8, Chunkang Chang9, Zhijian Xiao10
1 Blood Disease Hospital and Institute of Hematology, Chinese Academy of Medical Sciences, Tianjin, China
2 West China Hospital, Sichuan University, Sichuan, China
3 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
4 Henan Cancer Hospital, Henan, China
5 Zhongnan Hospital of Wuhan University, Wuhan, China
6 The Second Affiliated Hospital of Army Medical University, PLA, Chongqing, China
7 Beijing Tsinghua Changgung Hospital, Beijing, China
8 Guangdong Provincial People's Hospital, Guangzhou, China
9 Shanghai Sixth People's Hospital, Shanghai, China
10 MDS and MPN Center, Blood Disease Hospital and Institute of Hematology, Chinese Academy of Medical Sciences, Tianjin, China

Background: TQ05105(rovadicitinib) is a first-in-class, dual JAK/ROCK inhibitor, which has been approved in China for treatment of myelofibrosis (MF). TQ05105-I-01 is a single-arm, open-label, multicenter phase I study of rovadicitinib in myeloproliferative neoplasms (MPN) patients comprising a dose-escalation phase (N=15) and an expansion phase(N=49) (NCT04339400). Among MF patients at the TQ05105-I-01 study (N=45), the primary efficacy analysis reported a spleen volume reduction ≥35% (SVR35) rate of 28.9% at week 24, and a best SVR35 rate of 57.8%; the total symptom score reduction ≥50% (TSS50) rate was 71.1% at week 24, and a best TSS50 rate was 88.9%. Here we further report the detailed analysis of MF grade improvement from this study.

Methods: During the TQ05105-I-01 study, bone marrow biopsies were performed at screening, week 24, week 48, week 96, and end of follow-up in MF patients. Reticulin silver staining was used, and MF grade was assessed according to the 2016 WHO criteria. Kaplan-Meier analysis was applied to describe time to first MF grade improvement events, and 1-year improvement rate was estimated.

Results: Median follow-up time was 11.5months. Median age was 59.0, and percentage of male and female patients were 67.4% and 32.6%. A total of 43 patients received the target dose of 15 mg BID and had evaluable baseline and on-treatment biopsies. Baseline MF grade distribution was: MF-1, 9.3% (4/43); MF-2, 37.2% (16/43); MF-3, 53.5% (23/43). By week 24 assessment, 12 patients (27.9%) showed an improvement of ≥1 grade, and 26 patients (60.5%) showed stable MF grade compared to baseline. The best observed improvement rate during follow-up was 34.9% (15/43). Among the patients who experienced improvement, the improved state was sustained, including 3 patients (1 MF-3 and 2 MF-1 patients at baseline) who progressively improved to MF-0 grade during follow up. Estimated 1-year MF grade improvement rate was 39.5% (95% CI: 20.0%-54.2%).

Conclusions: In the TQ05105-I-01 study, rovadicitinib monotherapy at 15 mg BID demonstrated MF grade improvement. The improvement was sustained in patients during whole follow-up period. These data suggest that TQ05105 may have a potential advantage in delaying or reversing myelofibrosis progression.
Zefeng Xu: No relevant conflicts of interest to declare.